Recently, newly approved and upcoming treatment options include TNF-α inhibitors, S1P-receptor modulators, IL-12/IL-23 inhibitors, JAK/STAT inhibitors, stem-cell transplant and fecal microbiota transplant (FMT), etc. Although the treatment goal for IBD has been mainly focused on controlling inflammation, we also pursue the clinical development of a novel anti-fibrotic agent because intestinal fibrosis, which is a common complication in patients with long-term IBD, is not ameliorated by alleviating inflammation. This evidence concerns the gene SOAT1 and inflammatory bowel disease.